MedTrace Logo

A Registered Cohort Study on Color Discrimination Deficit Associated With Neurodegenerative Disorders.

NCT05639140 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2022-12-06

No results posted yet for this study

Summary

Color discrimination deficit is a common manifestation of Alzheimer's disease (AD). However, the pathophysiology of this dysfunction remains poorly understood. The aim of the present study was to evaluate color discrimination using the Farnsworth-Munsell 100 hue test in patients with AD and mild cognitive impairment (MCI), compared with age-matched control subjects. As a secondary aim, we evaluated whether the outcomes of these visual tests were associated with cognitive.

Conditions

Interventions

OTHER

Data collection

Neuropsychological assessment, FM-1OO, brain MRI, electroencephalogram and biomarker datas will be collected

Sponsors & Collaborators

  • Fujian Medical University Union Hospital

    lead OTHER

Eligibility

Min Age
30 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-01-01
Primary Completion
2025-07-01
Completion
2025-07-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05639140 on ClinicalTrials.gov